Trial Profile
A real-world study investigating safety and efficacy of fingolimod in patients with multiple sclerosis in the Czech Republic
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms GOLEMS
- 25 Nov 2016 New trial record
- 26 Oct 2016 Results published in the Clinical Drug Investigation